- Home
- VIAV vs DNLI Comparison
VIAV vs DNLI Comparison
Compare VIAV & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIAV
- DNLI
- Stock Information
- Founded
- VIAV 1923
- DNLI 2013
- Country
- VIAV United States
- DNLI United States
- Employees
- VIAV N/A
- DNLI N/A
- Industry
- VIAV Semiconductors
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VIAV Technology
- DNLI Health Care
- Exchange
- VIAV Nasdaq
- DNLI Nasdaq
- Market Cap
- VIAV 2.2B
- DNLI 2.1B
- IPO Year
- VIAV 1993
- DNLI 2017
- Fundamental
- Price
- VIAV $11.19
- DNLI $13.60
- Analyst Decision
- VIAV Buy
- DNLI Strong Buy
- Analyst Count
- VIAV 9
- DNLI 16
- Target Price
- VIAV $13.19
- DNLI $37.57
- AVG Volume (30 Days)
- VIAV 1.8M
- DNLI 1.3M
- Earning Date
- VIAV 05-01-2025
- DNLI 05-06-2025
- Dividend Yield
- VIAV N/A
- DNLI N/A
- EPS Growth
- VIAV N/A
- DNLI N/A
- EPS
- VIAV N/A
- DNLI N/A
- Revenue
- VIAV $1,007,000,000.00
- DNLI N/A
- Revenue This Year
- VIAV $10.56
- DNLI N/A
- Revenue Next Year
- VIAV $7.78
- DNLI $497.02
- P/E Ratio
- VIAV N/A
- DNLI N/A
- Revenue Growth
- VIAV N/A
- DNLI N/A
- 52 Week Low
- VIAV $6.60
- DNLI $13.30
- 52 Week High
- VIAV $12.91
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- VIAV 47.20
- DNLI 34.19
- Support Level
- VIAV $10.63
- DNLI $13.67
- Resistance Level
- VIAV $12.06
- DNLI $14.84
- Average True Range (ATR)
- VIAV 0.29
- DNLI 0.77
- MACD
- VIAV 0.01
- DNLI 0.12
- Stochastic Oscillator
- VIAV 39.16
- DNLI 9.90
About VIAV Viavi Solutions Inc.
Viavi Solutions Inc. is a global provider of network test, monitoring and assurance solutions to communications service providers, enterprises, network equipment manufacturers, civil government, military and avionics customers. The company also offers high-performance thin-film optical coatings, providing light management solutions to anti-counterfeiting, 3D sensing, electronics, automotive, defense and instrumentation markets. Its operating segments include Network Enablement, Service Enablement, and Optical Security and Performance Products. Geographically, it derives a majority of revenue from the United States.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.